跳至主要内容
临床试验/NCT03690999
NCT03690999已完成不适用

Impact of a Prebiotic Supplement on Microbiome, Immune System, and Metabolic Status of Older Adults

Stanford University2 个研究点 分布在 1 个国家目标入组 98 人开始时间: 2019年3月14日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
98
试验地点
2
主要终点
Immune status and function

研究概览

简要总结

An individual's immune and metabolic status is coupled to consumed carbohydrates. Complex carbohydrates that are not digested by human enzymes may influence host biology by impacting microbiota composition and function, or act in a yet-unknown microbiota-independent manner. Prebiotics offer a promising safe route to influence host health, possibly via the microbiota. However, it remains largely unknown to what extent immune function and metabolism can be modulated by prebiotics.

详细描述

The objective of this study is to define the impact of a prebiotic supplement on microbiome, immune system, and metabolic status in older adults. This study will determine the degree to which a prebiotic supplement can 1) regulate immune status and function including reducing chronic, systemic inflammation as assessed by high dimensional immune profiling, 2) alter microbiota composition and function, 3) impact the microbiota metabolites-potential normalizers of metabolic and immune dysfunction, and 4) alter metabolic markers.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
60 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 60 years old and older
  • Otherwise, healthy subjects willing and able to provide blood as well as stool specimens
  • Must be able to provide signed and dated informed consent and be willing to follow protocol

排除标准

  • Body Mass Index >= 40
  • LDL-C > 190 mg/dL
  • Systolic Blood Pressure >160 mmHg OR Diastolic Blood Pressure > 90 mmHg
  • Use of any of the following drugs/supplements within the last 2 months:
  • systemic antibiotics, antifungals, antivirals or antiparasitics (intravenous, intramuscular, or oral);
  • corticosteroids (intravenous, intramuscular, oral, nasal or inhaled)
  • cytokines
  • methotrexate or immunosuppressive cytotoxic agents
  • metformin
  • proton pump inhibitors (PPIs)
  • Regular use of any of the following medications:
  • regular dose aspirin (>81mg/day)
  • opiate pain medication
  • Use of large doses of commercial probiotics consumed (greater than or equal to 10-8 cfu or organisms per day) - includes tablets, capsules, lozenges, chewing gum or powders in which probiotic is a primary component. Ordinary dietary components such as fermented beverages/milks, yogurts, foods do not apply.
  • Acute disease at the time of enrollment. Acute disease is defined as the presence of a moderate or severe illness with or without fever. Examples include flu or gastroenteritis. Defer sampling until subject recover.
  • Chronic, clinically significant, unstable (unresolved, requiring on-going changes to medical management or medication) pulmonary, cardiovascular, gastrointestinal, hepatic or renal functional abnormality, as determined by medical history. Type 2 diabetes, type 1 diabetes, and dialysis will be excluded.
  • History of active uncontrolled gastrointestinal disorders or diseases including:
  • inflammatory bowel disease (IBD) including ulcerative colitis (mild-moderate-severe), Crohn's disease (mild-moderate-severe), or indeterminate colitis;
  • irritable bowel syndrome (IBS) (moderate-severe);
  • persistent, infectious gastroenteritis, colitis or gastritis, persistent or chronic diarrhea of unknown etiology, Clostridium difficile infection (recurrent) or Helicobacter pylori infection (untreated).
  • History of active cancer in the past 3 years except for squamous or basal cell carcinomas of the skin that have been medically managed by local excision.
  • Unstable dietary history as defined by major changes in diet during the previous month, where the subject has eliminated or significantly increased a major food group in the diet.
  • Recent history of chronic excessive alcohol consumption defined as more than five 1.5-ounce servings of 80 proof distilled spirits, five 12-ounce servings of beer or five 5-ounce servings of wine per day; or > 14 drinks/week.
  • Positive test for HIV, HBV or HCV.
  • Any confirmed or suspected condition/state of immunosuppression or immunodeficiency (primary or acquired) including HIV infection.
  • Surgery of the GI tract, with the exception of cholecystectomy and appendectomy, in the past five years. Any major bowel resection at any time.
  • Regular/frequent use of smoking or chewing tobacco, e-cigarettes, cigars or other nicotine-containing products.
  • Any confirmed or suspected autoimmune disease. Examples include multiple sclerosis and Graves disease.
  • Veganism.
  • Dairy allergies.

结局指标

主要结局

Immune status and function

时间窗: Baseline and 6 weeks

Change from baseline in Cytokine Response Score (CRS) at 6 weeks. The CRS is a single composite measure of cell-type specific activation of signaling pathways from ex vivo cytokine stimulation of blood samples. This provides a measure of immune response capacity which may be an indicator of immune fitness. The CRS will be calculated as described in Shen-Orr et al, Cell Systems, 2016. The CRS is the sum of 15 age-associated normalized cytokine responses identified in Shen-Orr et. al: In CD8+ T cells: IFNα pSTAT1, pSTAT3, pSTAT5; IL-6 pSTAT1, pSTAT3, pSTAT5; IFNγ pSTAT1; IL-21 pSTAT1; In CD4+ T cells: IFNα pSTAT5; IL-6 pSTAT5; In B cells: IFNα pSTAT1; in monocytes: IL-10 pSTAT3; IFNγ pSTAT3; IFNα pSTAT3; IL-6 pSTAT3. Each feature is calculated as the fold change of the protein in the stimulated condition relative to its level in the unstimulated condition. That value is then normalized to the feature's range: normalized = (x - xmin)/xmax. The 15 normalized values are summed for the CRS.

次要结局

  • Fasting Insulin(Baseline and 6 weeks)
  • HDL-cholesterol(Baseline and 6 weeks)
  • Microbiota composition(Baseline and 6 weeks)
  • Microbiota function(Baseline and 6 weeks)
  • Waist Circumference(Baseline and 6 weeks)
  • Fasting Glucose(Baseline and 6 weeks)
  • Weight(Baseline and 6 weeks)
  • Blood pressure(Baseline and 6 weeks)
  • Total Cholesterol(Baseline and 6 weeks)
  • Triglycerides(Baseline and 6 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Justin L. Sonnenburg

Associate Professor of Microbiology and Immunology

Stanford University

研究点 (2)

Loading locations...

相似试验